Literature DB >> 8140488

Single dose azithromycin treatment of gonorrhea and infections caused by C. trachomatis and U. urealyticum in men.

O Steingrímsson1, J H Olafsson, H Thórarinsson, R W Ryan, R B Johnson, R C Tilton.   

Abstract

BACKGROUND AND OBJECTIVES: Single dose regimens have advantages in the treatment of STD. Azithromycin has unique pharmacokinetics that may make single dose regimens feasible. Treatment with a single 1 g dose of azithromycin was compared to 100 mg doxycycline twice daily for seven days. STUDY
DESIGN: This was a randomized third-party blinded study on 183 male patients, 176 of whom could be evaluated for efficacy.
RESULTS: Chlamydia trachomatis was cultured from 148 patients, 79 receiving azithromycin and 69 receiving doxycycline. Six patients receiving azithromycin had positive cultures on follow-up, four were known to have had sexual intercourse with infected partners. Fifty-one patients had gonorrhea; 28 were treated with azithromycin and 23 with doxycycline. Neisseria gonorrhoeae was eradicated from all patients except one receiving azithromycin. He denied sexual exposure during follow-up. Sixty patients were infected with Ureaplasma urealyticum, 35 were treated with azithromycin and 25 with doxycycline. Five patients in each group had positive cultures on follow up. Three patients receiving azithromycin and two receiving doxycycline were known to have had sexual exposure during follow-up.
CONCLUSION: A single dose of azithromycin showed similar effectiveness as a 7-day regimen of doxycycline.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8140488     DOI: 10.1097/00007435-199401000-00009

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  19 in total

1.  Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations.

Authors:  L Zarantonelli; G Borthagaray; E H Lee; W M Shafer
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  Control of genital chlamydial infection.

Authors:  P R Gully; R W Peeling
Journal:  Can J Infect Dis       Date:  1994-05

3.  Trachoma, antibiotics and randomised controlled trials.

Authors:  B Shapiro; K Dickersin; T Lietman
Journal:  Br J Ophthalmol       Date:  2006-12       Impact factor: 4.638

Review 4.  Sexually transmitted infections.

Authors:  C Carne
Journal:  BMJ       Date:  1998-07-11

Review 5.  Antibiotic treatment of gonorrhoea--clinical evidence for choice.

Authors:  C Bignell
Journal:  Genitourin Med       Date:  1996-10

Review 6.  Treatment of sexually transmitted bacterial diseases in pregnant women.

Authors:  G G Donders
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

7.  Azithromycin levels in cervical mucus and plasma after a single 1.0g oral dose for chlamydial cervicitis.

Authors:  A M Worm; A Osterlind
Journal:  Genitourin Med       Date:  1995-08

8.  Pregnant women as a reservoir of undetected sexually transmitted diseases in rural South Africa: implications for disease control.

Authors:  A W Sturm; D Wilkinson; N Ndovela; S Bowen; C Connolly
Journal:  Am J Public Health       Date:  1998-08       Impact factor: 9.308

9.  Periodic health examination, 1996 update: 2. Screening for chlamydial infections. Canadian Task Force on the Periodic Health Examination.

Authors:  H D Davies; E E Wang
Journal:  CMAJ       Date:  1996-06-01       Impact factor: 8.262

10.  Macrolides: A Canadian Infectious Disease Society position paper.

Authors:  S McKenna; G Evans
Journal:  Can J Infect Dis       Date:  2001-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.